Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:COLL
CUSIPN/A
Phone781-713-3699
Debt
Debt-to-Equity Ratio3.91
Current Ratio0.83
Quick Ratio0.80
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$28.48 million
Price / Sales30.93
Cash FlowN/A
Price / CashN/A
Book Value$3.20 per share
Price / Book8.33
Profitability
EPS (Most Recent Fiscal Year)($2.47)
Net Income$-74,860,000.00
Net Margins-78.22%
Return on Equity-72.87%
Return on Assets-26.11%
Miscellaneous
Employees250
Outstanding Shares33,040,000
Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions
What is Collegium Pharmaceutical's stock symbol?
Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."
How were Collegium Pharmaceutical's earnings last quarter?
Collegium Pharmaceutical Inc (NASDAQ:COLL) announced its quarterly earnings data on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.02. The specialty pharmaceutical company had revenue of $63.70 million for the quarter, compared to analysts' expectations of $51.92 million. Collegium Pharmaceutical had a negative return on equity of 72.87% and a negative net margin of 78.22%. Collegium Pharmaceutical's revenue was up 2835.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.79) earnings per share. View Collegium Pharmaceutical's Earnings History.
What price target have analysts set for COLL?
7 brokerages have issued twelve-month target prices for Collegium Pharmaceutical's shares. Their predictions range from $26.00 to $40.00. On average, they expect Collegium Pharmaceutical's share price to reach $33.1667 in the next year. View Analyst Ratings for Collegium Pharmaceutical.
Who are some of Collegium Pharmaceutical's key competitors?
Some companies that are related to Collegium Pharmaceutical include Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Clovis Oncology (CLVS) and Xencor (XNCR).
Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the folowing people:
- Mr. Michael T. Heffernan, Founder, Chairman, Pres & CEO (Age 54)
- Mr. Paul J. Brannelly, Exec. VP & CFO (Age 45)
- Mr. Joseph J. Ciaffoni, Exec. VP & COO (Age 47)
- Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 43)
- Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 34)
When did Collegium Pharmaceutical IPO?
(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.
Has Collegium Pharmaceutical been receiving favorable news coverage?
News stories about COLL stock have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a news sentiment score of 0.12 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Collegium Pharmaceutical's major shareholders?
Collegium Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.99%), Rock Springs Capital Management LP (5.81%), Franklin Resources Inc. (4.45%), Massachusetts Financial Services Co. MA (1.25%), Prudential Financial Inc. (1.05%) and Summit Trail Advisors LLC (1.01%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, John A Fallon, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.
Which major investors are selling Collegium Pharmaceutical stock?
COLL stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Prudential Financial Inc., Wells Fargo & Company MN, Granite Investment Partners LLC, Franklin Resources Inc., Millennium Management LLC, Cortina Asset Management LLC and Massachusetts Financial Services Co. MA. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Longitude Capital Partners, Ll and Michael Thomas Heffernan. View Insider Buying and Selling for Collegium Pharmaceutical.
Which major investors are buying Collegium Pharmaceutical stock?
COLL stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Osterweis Capital Management Inc., Russell Investments Group Ltd., Tygh Capital Management Inc., Timpani Capital Management LLC, Fisher Asset Management LLC, UBS Group AG and EAM Global Investors LLC. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.
How do I buy shares of Collegium Pharmaceutical?
Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Collegium Pharmaceutical's stock price today?
One share of COLL stock can currently be purchased for approximately $26.66.
How big of a company is Collegium Pharmaceutical?
Collegium Pharmaceutical has a market capitalization of $881.95 million and generates $28.48 million in revenue each year. The specialty pharmaceutical company earns $-74,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Collegium Pharmaceutical employs 250 workers across the globe.
How can I contact Collegium Pharmaceutical?
Collegium Pharmaceutical's mailing address is 780 DEDHAM STREET SUITE 800, CANTON MA, 02021. The specialty pharmaceutical company can be reached via phone at 781-713-3699.
MarketBeat Community Rating for Collegium Pharmaceutical (COLL)
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
